In a nutshell This trial is examining the effectiveness of cabozantinib (Cabometyx) combined with atezolizumab (Tecentriq) for metastatic castration-resistant prostate cancer (mCRPC; cancer that is no longer responding to hormone therapy). The main outcomes to be measured are progression-free survival (PFS) and overall survival (OS) of...Read More
Current PSA level-Between 10 to 20 Posts on Medivizor
Can oral relugolix be used as androgen-deprivation therapy in advanced prostate cancer?
In a nutshell The study looked at whether oral relugolix (Orgovyx, Relumina) could be used to suppress testosterone in men with advanced prostate cancer compared to leuprolide (Lupron). This study showed that relugolix was associated with more rapid and effective suppression of testosterone levels when compared...Read More
Searching for patients with prostate cancer to test low-dose or high-dose brachytherapy
In a nutshell This phase 3 trial is examining the effectiveness and safety of low dose rate (LDR) vs high dose rate (HDR) prostate brachytherapy (BT) for patients with prostate cancer (PC). The main outcome to be measured will be the quality of life in terms of urinary symptoms. This trial is recruiting in British Columbia,...Read More
The use of stereotactic radiotherapy in patients with metastatic prostate cancer.
In a nutshell This study examined stereotactic body radiotherapy (SBRT) as a treatment for advanced prostate cancer. This study concluded that SBRT may be effective in the treatment of these patients. Some background Oligometastatic prostate cancer is cancer that is no longer confined to the prostate gland. However, it has not yet become...Read More
The timing of first biopsy and its effect on prostate cancer reclassification
In a nutshell The authors aimed to determine the influence of biopsy timing on prostate cancer reclassification during active surveillance. The authors concluded that the timing of the first biopsy was not related to an increased risk of cancer reclassification, but prostate specific antigen (PSA) and body mass index (BMI – measured based...Read More
The role of active surveillance for men with intermediate-risk prostate cancer
In a nutshell This study examined the role of active surveillance in the management of intermediate-risk prostate cancer. Researchers concluded that active surveillance is a safe management method for selected patients with favorable intermediate-risk disease. Men with more aggressive cancer cells may benefit from active treatment early on. Some...Read More
Hormone therapy during or after radiation therapy increases the risk of cardiovascular events
In a nutshell This study examined the effect of androgen deprivation therapy (ADT) on the risk of cardiovascular events (such as stroke or heart attack) in men treated with radiation therapy. Researchers concluded that ADT use during or after radiation therapy increases the risk of cardiovascular events. Some background Radiation therapy is a...Read More
High-risk prostate cancer: Is there a survival benefit when chemotherapy is administered before surgery?
In a nutshell This study examined the benefit of administering chemotherapy before prostate surgery in men with intermediate- to high-risk prostate cancer. Researchers reported preliminary evidence of a cancer-specific survival benefit when chemotherapy was administered before surgery. Some background Prostate surgery is a first-line treatment for...Read More
Searching for men with low- to intermediate-risk prostate cancer to test precise radiation therapy guided by an imaging technique
In a nutshell This trial aims to examine stereotactic radiosurgery guided by an imaging technique in treating low- to intermediate-risk prostate cancer. The main outcome to be investigated is treatment-related side effects and treatment response. The trial is recruiting in Ohio (USA). The details Stereotactic radiosurgery (SRS) uses a specially...Read More
Hormone therapy may shorten survival in African American men with low- or intermediate-risk prostate cancer
In a nutshell This study examined the effect of ethnicity on health outcomes with androgen deprivation therapy (ADT). Researchers reported shorter survival among African American men receiving ADT for low- or intermediate-risk prostate cancer compared to men of other ethnicities. Some background ADT is a type of hormone therapy used to treat...Read More
Comparing surgery and radiation therapies for high-risk prostate cancer
In a nutshell This study compared prostate surgery and radiation therapy in treating high-risk prostate cancer. Authors reported similar survival benefits with both treatments. However, high doses of total radiation combined with hormone therapy was associated with the lowest risk of disease progression. Some background Prostate surgery and...Read More
Adding radiation to hormone therapy is effective for locally advanced prostate cancer
In a nutshell This study examined the benefit of combining radiation therapy with androgen deprivation therapy (ADT) in older men and in men with aggressive cancer cells. Researchers reported reduced mortality risks with combination therapy in all groups studied. Some background Radiation therapy is a common treatment for localized...Read More